Michela Buglione
Overview
Explore the profile of Michela Buglione including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
1306
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bonu M, Triggiani L, Guerini A, Buglione M, Magrini S
Int J Radiat Oncol Biol Phys
. 2025 Mar;
121(5):1396-1397.
PMID: 40089342
No abstract available.
2.
Guerini A, Mataj E, Borghetti P, Triggiani L, Pegurri L, Nici S, et al.
Adv Radiat Oncol
. 2025 Feb;
10(3):101696.
PMID: 39911722
Purpose: Multiple myeloma (MM) tends to develop resistance to systemic therapy through multiple mechanisms that might as well induce radioresistance, as suggested by preclinical studies. The aim of the present...
3.
Guerini A, Marvaso G, Tonoli S, Corrao G, Teriaca M, Sepulcri M, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796715
Methods And Materials: Patients with ongoing or planned anticancer treatment at 19 Italian Radiation Oncology centers were included in the study retrospectively from 3 February 2020 to 31 December 2020...
4.
Rondi P, Tomasoni M, Cunha B, Rampinelli V, Bossi P, Guerini A, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682115
Background/objectives: Adenoid Cystic Carcinoma (AdCC) is a rare malignant salivary gland tumor, with high rates of recurrence and distant metastasis. This study aims to stratify patients Relapse-Free Survival (RFS) using...
5.
Bonu M, Georgopulos A, Mataj E, Domina A, Granello L, Morelli V, et al.
Arch Esp Urol
. 2024 May;
77(3):315-317.
PMID: 38715173
No abstract available.
6.
Borghetti P, Costantino G, Santoro V, Mataj E, Singh N, Vitali P, et al.
In Vivo
. 2024 Apr;
38(3):1359-1366.
PMID: 38688600
Background/aim: Overall survival (OS)-predictive models to clinically stratify patients with stage I Non-Small Cell Lung Cancer (NSCLC) undergoing stereotactic body radiation therapy (SBRT) are still unavailable. The aim of this...
7.
Bonu M, Nicosia L, Turkaj A, Pastorello E, Vitali P, Frassine F, et al.
Radiol Med
. 2024 Feb;
129(3):497-506.
PMID: 38345714
Background: Stereotactic radiotherapy (SRT) and Proton therapy (PT) are both options in the management of liver lesions. Limited clinical-dosimetric comparison are available. Moreover, dose-constraint routinely used in liver PT and...
8.
Guerini A, Nici S, Magrini S, Riga S, Toraci C, Pegurri L, et al.
Technol Cancer Res Treat
. 2023 Sep;
22:15330338231199286.
PMID: 37774771
Background: Possible advantages of magnetic resonance (MR)-guided radiation therapy (MRgRT) for the treatment of brain tumors include improved definition of treatment volumes and organs at risk (OARs) that could allow...
9.
Levis M, Campbell B, Matrone F, Grapulin L, Di Russo A, Buglione M, et al.
Int J Radiat Oncol Biol Phys
. 2023 Feb;
116(5):1008-1018.
PMID: 36822373
Purpose: In this multicenter collaboration, we report real-world data in the largest published series of long-term outcomes for patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL) treated with peritransplant radiation therapy...
10.
Tonetto F, Magli A, Moretti E, Guerini A, Tullio A, Reverberi C, et al.
J Clin Med
. 2022 Dec;
11(23).
PMID: 36498488
Objective: This paper illustrates the results of a mono-institutional registry trial, aimed to test whether gastrointestinal (GI) and genitourinary (GU) toxicity rates were lower in localized prostate cancer patients treated...